Clinical trial · no report yet · Phase 3
SASCIA
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
- NCT04595565 ↗
- Active, not recruiting
- GBG Forschungs GmbH
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Podcasts | 8 | |
| YouTube | 5 | |
| X threads | 1 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase III Postneoadjuvant Study Evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in Primary HER2-negative Breast Cancer Patients With High Relapse Risk After Standard Neoadjuvant Treatment - SASCIA
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- HER2-negative Breast Cancer; Triple Negative Breast Cancer
- Interventions
- Capecitabine; Carboplatin; Cisplatin; Sacituzumab govitecan
- Arms
- Sacituzumab govitecan · Experimental
- Treatment of physician´s choice · Other
- Enrollment
- 1,332 (estimated)
- Primary outcomes
- Invasive disease free survival (iDFS) between patients treated with sacituzumab govitecan vs. treatment of physician's choice.
- Sponsor
- GBG Forschungs GmbH with Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER
- Start
- Oct 28, 2020
- Primary completion
- Mar 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04595565 · updated Apr 22, 2026
Publications
linked from the registry- Marmé F, Hanusch C, Furlanetto J, et al. Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment. ESMO Breast 2022; 58O, proffered paper presentation. https://doi.org/10.1016/j.annonc.2022.03.075